Sonic Healthcare Limited (SHL) AI Stock Analysis

Compare

168 Followers

Top Page

Sonic Healthcare Limited

(Sydney:SHL)

Select Model

Outperform 70 (OpenAI - 5.2)

Rating:70Outperform

Price Target:

AU$26.00

▲(12.99% Upside)

Action:UpgradedDate:02/20/26

The score is driven primarily by solid financial performance (revenue growth and strong free cash flow) and a supportive earnings outlook with maintained EBITDA guidance and modest margin expansion. Valuation is helped by a strong dividend yield, while the main offsets are mixed technical momentum (negative MACD) and business headwinds highlighted on the call (U.S. margin pressure, working-capital/collections issues, higher net debt, and FX uncertainty).

Positive Factors

Strong Cash Generation

Sonic's meaningful FCF growth and high operating-cash conversion provide durable funding for acquisitions, integration, dividends and debt reduction. Reliable cash conversion supports capital allocation flexibility and resilience through reimbursement cycles and capex requirements.

Diversified Organic Growth

Sustained organic growth across multiple markets and service lines reduces reliance on any single geography or payer. Geographic and product diversification (pathology, radiology, clinical services) supports revenue stability and allows Sonic to compound scale benefits over the medium term.

Margin Expansion & Operating Leverage

Incremental margin improvement and identified productivity gains indicate capture of operating leverage from scale, lab consolidation and automation. Margin expansion durability is supported by planned hub labs, procurement savings and digital pathology rollout.

Negative Factors

U.S. Margin Pressure

Structural pressure in the U.S. market, including low organic growth and ongoing AP practice rationalisation, can persistently weigh on group margins given the U.S. scale. Restructuring costs and slower local recovery may delay margin convergence for several quarters.

Higher Net Debt from M&A & Property

Acquisition and property spending materially increased leverage, reducing immediate balance-sheet flexibility. Elevated net debt raises interest and refinancing sensitivity, constraining capital deployment choices and making earnings more exposed to integration execution risk.

Working-Capital / Collections Disruption

Prolonged billing and collections disruption can structurally inflate receivables and working-capital requirements, tying up cash and increasing funding needs. Delays in realising receivables reduce free-cash-flow reliability until billing operations normalise.

Sonic Healthcare Limited (SHL) vs. iShares MSCI Australia ETF (EWA)

Market Cap

AU$11.37B

Dividend Yield4.69%

Average Volume (3M)1.62M

Price to Earnings (P/E)10.6

Beta (1Y)0.70

Revenue Growth9.44%

EPS Growth-0.37%

CountryAU

Employees42,000

SectorHealthcare

Sector Strength45

IndustryMedical - Diagnostics & Research

Share Statistics

EPS (TTM)0.50

Shares Outstanding494,237,950

10 Day Avg. Volume1,694,025

30 Day Avg. Volume1,619,425

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)1.55

Price to Sales (P/S)1.34

P/FCF Ratio13.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$25.04

Price Target Upside8.82% Upside

Rating ConsensusHold

Number of Analyst Covering10

EPS Forecast (FY)1.22

Revenue Forecast (FY)AU$10.96B

Sonic Healthcare Limited Business Overview & Revenue Model

Company DescriptionSonic Healthcare Limited offers medical diagnostic services to medical practitioners, hospitals, community health services, and their collective patients. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It also offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, after-hours general practice services, general practice IT solutions, and community-based healthcare services. The company operates in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, Belgium, and internationally. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.

How the Company Makes MoneySonic Healthcare generates revenue primarily through its extensive portfolio of diagnostic services, which includes pathology, radiology, and other medical testing. The company earns money by charging healthcare providers and patients for these services, often operating on a fee-for-service model. Key revenue streams include pathology services, which involve the analysis of blood and other samples, and radiology services, which encompass imaging techniques such as X-rays and MRIs. Additionally, Sonic Healthcare benefits from partnerships with hospitals, clinics, and healthcare networks, which provide a steady stream of clients and enhance service delivery. The company also leverages economies of scale and operational efficiencies to optimize its cost structure, thereby improving profitability. Furthermore, SHL's international presence allows it to tap into diverse healthcare markets, contributing to its overall financial performance.

Sonic Healthcare Limited Earnings Call Summary

Earnings Call Date:Feb 18, 2026

(Q2-2026)

% Change Since: |

Next Earnings Date:Aug 26, 2026

Earnings Call Sentiment Positive

The call presents a broadly positive operational and financial position — solid H1 results, maintained full-year EBITDA guidance, margin expansion (+30 bps), diversified organic growth across key markets (Germany, Australia, UK, Radiology) and progress on acquisitions, digital pathology and capital management initiatives (dividend increase, sale-and-leaseback program). Headwinds are meaningful but generally manageable: U.S. margin pressure and restructuring, slower revenue-collection benefits pushed into FY2027, working-capital distortion from a Change Healthcare cyber incident, higher net debt from acquisitions/property spending, FX uncertainty and pending Australian wage decisions. Management emphasizes operating leverage, synergy capture and disciplined capital allocation to address these challenges.

Q2-2026 Updates

Positive Updates

Strong H1 Financial Results

Revenue of $5.445 billion, EBITDA of $907 million and net profit of $262 million for H1 FY2026; EPS AUD 0.531. Management maintained full-year adjusted EBITDA guidance of $1.87bn–$1.95bn (constant currency).

Organic Revenue Growth

Group organic growth of 5% in H1 FY2026, with particularly strong contributions from Australian Pathology (organic +5%) and other divisions.

Regional Outperformance and High-Growth Markets

Germany delivered 40% revenue growth on a constant currency basis (organic +5%); United Kingdom organic growth +24% driven by Hertfordshire & West Essex contract; Radiology organic revenue growth +7%; Sonic Clinical Services revenue +5% with EBITDA growth +20% (from a low base).

Margin Expansion and Operating Leverage

Adjusted EBITDA margins increased by ~30 basis points year-on-year (H1 2025 → H1 2026) and management highlights operating leverage and synergy realization across most businesses.

Acquisitions and Integration Progress

LADR (Germany) settled 1 July 2025 and integration across 16 workstreams is progressing to plan; Cairo Diagnostics and ThyroSeq included in an expanded Advanced Diagnostics division; >60% of dermatopathology volume now on proprietary PathologyWatch digital platform.

Capital Management and Balance Sheet Flexibility

Interim dividend increased by 2.3% to AUD 0.45 (60% franked); target medium-term payout ratio 70–80%. Debt cover ratio at 2.5x and available headroom ~US$1 billion before interim dividend. Sale-and-leaseback program initiated to unlock capital and fund potential on-market buybacks.

Reduced Depreciation Guidance and More Transparency Below EBITDA

Depreciation forecast lowered to $770m–$780m (constant currency). Management provided tighter below-EBITDA guidance (depreciation, interest and tax rate guidance at 27%).

Operational Wins and Productivity Initiatives

Major lab platform procurement completed delivering substantial savings; new hub labs (e.g., Watford, Melbourne Docklands) and automation investments underway; partnership with National Lung Cancer Screening Program boosting CT volumes.

Negative Updates

U.S. Margin Pressure and Restructuring

Margin decline in U.S. operations due to low organic revenue growth and restructuring costs; anatomical pathology represents ~1/3 of U.S. revenue (~$400m of ~$1.4bn) and rationalization of nine AP practices is underway. Some further, though described as de minimis, restructuring costs expected in H2.

Slower-than-Expected Revenue-Collection Benefits

Enhanced U.S. revenue collection system is delivering benefits more slowly and to a lesser extent than previously expected; an earlier-guidance benefit of ~US$20–25m of earnings is likely to be deferred into FY2027.

Change Healthcare Cyber Incident Impacting Working Capital

A cyber breach of Change Healthcare (Feb 2024) disrupted billing/collections and resulted in inflated receivables and temporary vendor advances/loans on the balance sheet; management expects this to resolve by 30 June but it contributed to higher net debt/working capital in H1.

Net Debt Increase from Acquisitions and Property Investment

Net debt rose due to LADR and Cairo Diagnostics acquisitions and the Docklands property purchase (~US$100m), increasing leverage relative to some market expectations despite available headroom of ~US$1bn.

FX Uncertainty and Reduced Tailwind

Foreign-exchange tailwind that supported H1 will be materially less for the full year; based on current rates H2 may see a reduced tailwind or an EBITDA headwind versus H1, introducing earnings currency risk and uncertainty.

Lab/Contract Dilution and One-off Acquisition Effects

LADR initial margin lower than Sonic average (as expected); Hertfordshire & West Essex contract improving but still dilutive; German EBM minimum KV quota change produced an expected ~1% revenue impact and contributed to headwinds being cycled through in 2026.

Wage Pressure and Industrial Uncertainty in Australia

Phlebotomist award changes are expected to have a sub–AUD2m FY2026 impact (including one-off leave provision readjustment); the Fair Work Commission's health professional determination (likely FY2027 impact) remains unresolved and could create further wage cost pressure absent government offsets.

CapEx and Property-Related Spend Elevated

CapEx in H1 was higher than prior periods due to property-related investments (Docklands purchase and build-outs, UK/Swiss lab projects); next 6 months property spend cited at ~AUD 20–30m with underlying maintenance CapEx estimated ~3–3.5% of revenue (excluding properties).

Company Guidance

Management maintained full‑year adjusted EBITDA guidance of AUD 1.87–1.95 billion on a constant‑currency basis, after reporting H1 revenue of AUD 5.445 billion, H1 EBITDA of AUD 907 million, H1 net profit of AUD 262 million and EPS of AUD 0.531; group organic growth was ~5% with adjusted EBITDA margins up 30 basis points year‑on‑year. They tightened below‑the‑line guidance to depreciation of AUD 770–780 million (constant currency), an interest‑expense increase of about 15% year‑on‑year (constant currency) and an effective tax rate of 27%; guidance excludes property sale gains, assumes only completed acquisitions and prevailing interest rates. Capital management metrics and priorities include maintaining an investment‑grade balance sheet (debt cover ratio ~2.5x), available headroom of ~AUD 1.0 billion before the interim dividend, a progressive interim dividend of AUD 0.45 (up 2.3%, 60% franked, record 5 Mar, pay 19 Mar) and a medium‑term dividend payout target of 70–80% of net profit, with potential sale‑and‑leaseback proceeds earmarked for share buybacks; management also flagged an FX tailwind for the full year that will be smaller than H1 and noted H1 acquisition costs of AUD 8 million.

Sonic Healthcare Limited Financial Statement Overview

Summary

Solid fundamentals supported by consistent revenue growth (+3.38%) and strong cash generation (free cash flow +16.63%, operating cash flow to net income 2.53). Offsetting factors include higher leverage (debt-to-equity 0.62) and some profitability/return pressure (net margin 5.32%, ROE 6.17%).

Income Statement

Positive

Sonic Healthcare Limited has demonstrated consistent revenue growth, with a 3.38% increase in the latest year. The gross profit margin has improved to 33.05%, indicating efficient cost management. However, the net profit margin has slightly decreased to 5.32%, suggesting some pressure on net earnings. The EBIT margin remains stable at 9.71%, reflecting solid operational efficiency.

Balance Sheet

Positive

The company's debt-to-equity ratio has increased to 0.62, indicating a higher reliance on debt financing. Return on equity has slightly decreased to 6.17%, which may concern investors looking for high returns. However, the equity ratio remains robust at 51.87%, showing a strong equity base relative to total assets.

Cash Flow

Positive

Sonic Healthcare's free cash flow has grown by 16.63%, showcasing strong cash generation capabilities. The operating cash flow to net income ratio is 2.53, indicating efficient conversion of income into cash. The free cash flow to net income ratio is 0.74, reflecting a healthy cash flow position relative to net earnings.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	10.39B	9.65B	8.93B	8.14B	9.31B	8.75B
Gross Profit	3.07B	3.19B	2.33B	6.87B	3.41B	7.14B
EBITDA	1.29B	1.24B	1.66B	1.72B	2.83B	2.56B
Net Income	539.40M	513.60M	511.09M	684.98M	1.46B	1.32B
Balance Sheet
Total Assets	17.03B	16.05B	14.83B	13.56B	13.11B	12.27B
Cash, Cash Equivalents and Short-Term Investments	557.12M	673.77M	645.00M	797.99M	780.00M	899.83M
Total Debt	7.34B	5.17B	4.52B	3.10B	3.01B	3.23B
Total Liabilities	8.31B	7.58B	6.75B	5.64B	5.68B	5.77B
Stockholders Equity	8.56B	8.32B	7.92B	7.74B	7.27B	6.38B
Cash Flow
Free Cash Flow	865.97M	960.55M	492.01M	974.02M	1.85B	1.68B
Operating Cash Flow	1.36B	1.30B	1.07B	1.47B	2.23B	2.04B
Investing Cash Flow	-1.28B	-577.62M	-1.81B	-580.04M	-989.18M	-386.75M
Financing Cash Flow	-70.48M	-735.93M	592.41M	-911.51M	-1.35B	-1.95B

Sonic Healthcare Limited Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price23.01

Price Trends

50DMA

22.27

Positive

100DMA

21.92

Positive

200DMA

23.24

Negative

Market Momentum

MACD

0.30

Negative

RSI

58.21

Neutral

STOCH

88.91

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SHL, the sentiment is Neutral. The current price of 23.01 is above the 20-day moving average (MA) of 22.15, above the 50-day MA of 22.27, and below the 200-day MA of 23.24, indicating a neutral trend. The MACD of 0.30 indicates Negative momentum. The RSI at 58.21 is Neutral, neither overbought nor oversold. The STOCH value of 88.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:SHL.

Sonic Healthcare Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHL	70 Outperform	AU$11.37B	10.64	6.32%	4.69%	9.44%	-0.37%
MVF	67 Neutral	AU$263.00M	10.00	10.25%	6.22%	6.65%	―
ACL	59 Neutral	AU$420.91M	23.92	18.59%	4.60%	6.73%	37.16%
IDX	55 Neutral	AU$905.69M	26.42	0.94%	2.65%	33.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HLS	46 Neutral	€479.25M	-5.40	-67.21%	―	-23.02%	33.11%
GSS	41 Neutral	AU$22.03M	-2.23	-36.16%	―	62.81%	16.37%

* Healthcare Sector Average

Performance Comparison

AU:SHL

Sonic Healthcare Limited

23.20

-2.95

-11.27%

AU:HLS

Healius Limited

0.64

-0.42

-39.70%

AU:GSS

Genetic Signatures Ltd.

0.10

-0.43

-81.13%

AU:IDX

Integral Diagnostics Ltd.

2.38

0.19

8.73%

AU:ACL

Australian Clinical Labs Ltd

2.22

-0.77

-25.75%

AU:MVF

Monash IVF Group Ltd

0.67

-0.50

-43.07%

Sonic Healthcare Limited Corporate Events

Sonic Healthcare Announces Director’s Interest Change as Part of Long-term Incentive Plan

Nov 24, 2025

Sonic Healthcare Limited announced a change in the director’s interest, with James Pacey Newcombe acquiring 345,342 unlisted options and 50,481 unlisted performance rights over ordinary shares. These securities will vest in 2028, contingent on performance criteria, as part of the company’s long-term incentive plan approved at the 2025 AGM. This move reflects the company’s strategy to align executive compensation with performance, potentially impacting its operational focus and stakeholder interests by incentivizing leadership to meet long-term goals.

The most recent analyst rating on (AU:SHL) stock is a Hold with a A$23.50 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.

Sonic Healthcare Limited Updates Director’s Interest Notice

Nov 24, 2025

Sonic Healthcare Limited announced a change in the director’s interest notice, specifically concerning Christopher David Wilks. The notice details changes in the number of ordinary shares and unlisted options held directly and indirectly by the director, reflecting adjustments in the company’s stock and options management. This update is significant for stakeholders as it highlights the company’s ongoing commitment to transparency in its corporate governance practices.

Sonic Healthcare Issues New Employee Incentive Securities

Nov 21, 2025

Sonic Healthcare Limited has announced the issuance of 111,971 performance rights under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize its employees, potentially enhancing workforce motivation and aligning employee interests with company performance, thereby strengthening its market position.

Sonic Healthcare Issues New Unquoted Equity Securities

Nov 21, 2025

Sonic Healthcare Limited announced the issuance of 730,792 unquoted equity securities under an employee incentive scheme. This move is part of the company’s strategy to incentivize employees and align their interests with the company’s growth objectives, potentially impacting its operational efficiency and market positioning.

Sonic Healthcare Announces Director Departure and Securities Update

Nov 21, 2025

Sonic Healthcare Limited has announced the cessation of Colin Stephen Goldschmidt as a director, effective November 20, 2025. The notice details Goldschmidt’s interests in various securities, including ordinary shares, unlisted options, and performance rights, which are part of the company’s employee option and performance rights plans. This transition may impact the company’s governance structure and could have implications for its strategic direction and stakeholder relations.

Sonic Healthcare Announces Director’s Interest Change

Nov 21, 2025

Sonic Healthcare Limited announced a change in the director’s interest, specifically regarding Colin Stephen Goldschmidt’s holdings. The notice details the number of shares and options held by the director, including various unlisted options and performance rights with specific vesting periods and exercise prices. This change in director’s interest could impact the company’s governance and potentially influence investor perceptions.

Sonic Healthcare Limited Appoints New Director with Strategic Share Options

Nov 21, 2025

Sonic Healthcare Limited has announced the appointment of James Pacey Newcombe as a director, effective November 20, 2025. As part of his role, Newcombe holds various unlisted options over ordinary shares in the company, which are part of the Sonic Healthcare Limited Employee Option Plan. This appointment and the associated options indicate a strategic move to align the interests of the director with the long-term goals of the company, potentially impacting its governance and operational strategies.

Sonic Healthcare Limited Announces Cessation of Securities

Nov 21, 2025

Sonic Healthcare Limited announced the cessation of 4,546,633 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies.

Sonic Healthcare’s 2025 AGM Resolutions Passed with Strong Shareholder Support

Nov 20, 2025

Sonic Healthcare Limited held its 2025 Annual General Meeting as a hybrid event, where all proposed resolutions were approved by shareholders through a poll. This outcome reflects strong shareholder support and may positively impact the company’s governance and strategic direction, reinforcing its position in the healthcare industry.

The most recent analyst rating on (AU:SHL) stock is a Hold with a A$24.00 price target. To see the full list of analyst forecasts on Sonic Healthcare Limited stock, see the AU:SHL Stock Forecast page.

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 20, 2026